Table of Content

Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Growth Opportunity Analysis
Scope of Analysis
Market Segmentation by Product Type
Market Segmentation by Cell Expression System Type
Market Segmentation by Service Type
Key Regional Competitors in the Bio-CDMO Market
Growth Drivers
Growth Restraints
Growth Environment—Bio-CDMO Market
Biologics Pipeline Overview
Bio-CDMO Business Model—Value Chain Expansion
Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine
Impact of Biosimilar Launches on CDMOs
Key Emerging Trends in the Bio-CDMO Industry
Key Emerging Trends in the Bio-CDMO Industry (continued)
New Modalities Paving the Way for New Entrants
New Modalities Paving Way for New Entrants
Product Distribution of Marketed Biologics in 2022
Distribution of Bioprocessing Technique—Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing
Regional Distribution of Total Biomanufacturing Capacity
Growth Opportunity Analysis—Bio-CDMO Industry
Key Growth Metrics for the Global Bio-CDMO Market
Forecast Framework—Bio-CDMO Market Sizing
Forecast Methodology—Bio-CDMO Market
Forecast Assumptions and Considerations—Bio-CDMO Market
Revenue Forecast—Global Bio-CDMO Market
Revenue Forecast Analysis—Global Bio-CDMO Market
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Forecast by Cell Expression System Type
Revenue Forecast Analysis for Mammalian Expression Systems
Revenue Forecast Analysis for Microbial Expression Systems
Revenue Forecast Analysis for Other Expression Systems
Revenue Split by Service Type
Competitive Environment
Revenue Share Estimation—Top Bio-CDMO Market Participants
Revenue Share Analysis—Top Bio-CDMO Market Participants
Growth Opportunity Universe
Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe
Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe (continued)
Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia
Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia (continued)
Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities
Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities (continued)
Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing
Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing (continued)
Growth Opportunity 5: Discovery and Preclinical Services for New Modalities
Growth Opportunity 5: Discovery and Preclinical Services for New Modalities (continued)
Growth Opportunity 6: Purpose-built PAT Services for CGT
Growth Opportunity 6: Purpose-built PAT Services for CGT (continued)
Next Steps
List of Exhibits
Legal Disclaimer